000130464 001__ 130464
000130464 005__ 20240228143435.0
000130464 0247_ $$2doi$$a10.1093/jnci/djv377
000130464 0247_ $$2pmid$$apmid:26668184
000130464 0247_ $$2pmc$$apmc:PMC4849806
000130464 0247_ $$2ISSN$$a0027-8874
000130464 0247_ $$2ISSN$$a0198-0157
000130464 0247_ $$2ISSN$$a1460-2105
000130464 0247_ $$2altmetric$$aaltmetric:4877244
000130464 037__ $$aDKFZ-2017-05543
000130464 041__ $$aeng
000130464 082__ $$a610
000130464 1001_ $$0P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aSahm, Felix$$b0$$eFirst author$$udkfz
000130464 245__ $$aTERT Promoter Mutations and Risk of Recurrence in Meningioma.
000130464 260__ $$aOxford$$bOxford Univ. Press$$c2016
000130464 3367_ $$2DRIVER$$aarticle
000130464 3367_ $$2DataCite$$aOutput Types/Journal article
000130464 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524813479_4217
000130464 3367_ $$2BibTeX$$aARTICLE
000130464 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000130464 3367_ $$00$$2EndNote$$aJournal Article
000130464 520__ $$aThe World Health Organization (WHO) classification and grading system attempts to predict the clinical course of meningiomas based on morphological parameters. However, because of high interobserver variation of some criteria, more reliable prognostic markers are required. Here, we assessed the TERT promoter for mutations in the hotspot regions C228T and C250T in meningioma samples from 252 patients. Mutations were detected in 16 samples (6.4% across the cohort, 1.7%, 5.7%, and 20.0% of WHO grade I, II, and III cases, respectively). Data were analyzed by t test, Fisher's exact test, log-rank test, and Cox proportional hazard model. All statistical tests were two-sided. Within a mean follow-up time in surviving patients of 68.1 months, TERT promoter mutations were statistically significantly associated with shorter time to progression (P < .001). Median time to progression among mutant cases was 10.1 months compared with 179.0 months among wild-type cases. Our results indicate that the inclusion of molecular data (ie, analysis of TERT promoter status) into a histologically and genetically integrated classification and grading system for meningiomas increases prognostic power. Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.
000130464 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000130464 588__ $$aDataset connected to CrossRef, PubMed,
000130464 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000130464 650_7 $$0EC 2.7.7.49$$2NLM Chemicals$$aTERT protein, human
000130464 650_7 $$0EC 2.7.7.49$$2NLM Chemicals$$aTelomerase
000130464 7001_ $$0P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aSchrimpf, Daniel$$b1$$udkfz
000130464 7001_ $$aOlar, Adriana$$b2
000130464 7001_ $$0P:(DE-HGF)0$$aKoelsche, Christian$$b3
000130464 7001_ $$0P:(DE-HGF)0$$aReuss, David$$b4
000130464 7001_ $$aBissel, Juliane$$b5
000130464 7001_ $$aKratz, Annekathrin$$b6
000130464 7001_ $$aCapper, David$$b7
000130464 7001_ $$aSchefzyk, Sebastian$$b8
000130464 7001_ $$0P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aHielscher, Thomas$$b9$$udkfz
000130464 7001_ $$aWang, Qianghu$$b10
000130464 7001_ $$aSulman, Erik P$$b11
000130464 7001_ $$aAdeberg, Sebastian$$b12
000130464 7001_ $$aKoch, Arend$$b13
000130464 7001_ $$aOkuducu, Ali Fuat$$b14
000130464 7001_ $$aBrehmer, Stefanie$$b15
000130464 7001_ $$aSchittenhelm, Jens$$b16
000130464 7001_ $$aBecker, Albert$$b17
000130464 7001_ $$aBrokinkel, Benjamin$$b18
000130464 7001_ $$aSchmidt, Melissa$$b19
000130464 7001_ $$aUll, Theresa$$b20
000130464 7001_ $$aGousias, Konstantinos$$b21
000130464 7001_ $$aKessler, Almuth Friederike$$b22
000130464 7001_ $$aLamszus, Katrin$$b23
000130464 7001_ $$aDebus, Jürgen$$b24
000130464 7001_ $$aMawrin, Christian$$b25
000130464 7001_ $$aKim, Yoo-Jin$$b26
000130464 7001_ $$aSimon, Matthias$$b27
000130464 7001_ $$aKetter, Ralf$$b28
000130464 7001_ $$aPaulus, Werner$$b29
000130464 7001_ $$aAldape, Kenneth D$$b30
000130464 7001_ $$aHerold-Mende, Christel$$b31
000130464 7001_ $$0P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$avon Deimling, Andreas$$b32$$eLast author$$udkfz
000130464 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djv377$$gVol. 108, no. 5, p. djv377 -$$n5$$pdjv377 -$$tJournal of the National Cancer Institute$$v108$$x1460-2105$$y2016
000130464 909CO $$ooai:inrepo02.dkfz.de:130464$$pVDB
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1f4b408b9155beb2a8f7cba4d04fe88$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e54a1e0999c1d8c95869ef9188b794cc$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)743a4a82daab55306a2c88b9f6bf8c2f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000130464 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a8a10626a848d31e70cfd96a133cc144$$aDeutsches Krebsforschungszentrum$$b32$$kDKFZ
000130464 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000130464 9141_ $$y2016
000130464 915__ $$0StatID:(DE-HGF)0400$$2StatID$$aAllianz-Lizenz / DFG
000130464 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000130464 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2015
000130464 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000130464 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000130464 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000130464 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000130464 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000130464 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000130464 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000130464 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000130464 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000130464 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000130464 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000130464 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000130464 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2015
000130464 9201_ $$0I:(DE-He78)G380-20160331$$kG380$$lKKE Neuropathologie$$x0
000130464 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000130464 9201_ $$0I:(DE-He78)L101-20160331$$kL101$$lDKTK Heidelberg$$x2
000130464 980__ $$ajournal
000130464 980__ $$aVDB
000130464 980__ $$aI:(DE-He78)G380-20160331
000130464 980__ $$aI:(DE-He78)C060-20160331
000130464 980__ $$aI:(DE-He78)L101-20160331
000130464 980__ $$aUNRESTRICTED